Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed + gemcitabine + bevacizumab
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen of three anticancer drugs—pemetrexed, gemcitabine, and bevacizumab—used primarily in the treatment of advanced non-small cell lung cancer (NSCLC). Pemetrexed is an antifolate chemotherapy agent that inhibits several folate-dependent enzymes involved in nucleotide synthesis, thereby disrupting DNA replication and cell division[8]. Gemcitabine is a nucleoside analog that interferes with DNA synthesis by incorporating into DNA strands and inhibiting ribonucleotide reductase. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth. The combination has been investigated as first-line therapy for advanced NSCLC, showing activity and tolerability in phase II clinical trials[1][2]. Each drug contributes distinct mechanisms to inhibit tumor proliferation and survival.
- Other names
- pemetrexed disodium (for pemetrexed)dFdC (for gemcitabine)rhuMAb VEGF (for bevacizumab)
02
Targets
ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DHFR (Dihydrofolate reductase)GART (GAR transformylase)RNR (Ribonucleotide reductase)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on pemetrexed + gemcitabine + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed + gemcitabine + bevacizumab.